Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity

Clinical Biochemistry

Volumn 48, Issue 4-5, 2015, Pages 223-235

  Christenson, Eric S ^a   James, Theodore ^a   Agrawal, Vineet ^a   Park, Ben H ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Anthracyclines; Cardiac toxicity; Chemotherapy; Natriuretic peptides; Troponin

Indexed keywords

ANTHRACYCLINE; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; DASATINIB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; ENDOTHELIN 1; FLUOROURACIL; GLYCOGEN PHOSPHORYLASE; IMATINIB; MYELOPEROXIDASE; NATRIURETIC FACTOR; NILOTINIB; PROTEIN; RAZOXANE; S6 KINASE; SORAFENIB; ST 2 PROTEIN; SUNITINIB; TAXANE DERIVATIVE; TRASTUZUMAB; TROPONIN I; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BRAIN NATRIURETIC PEPTIDE; TROPONIN T;

CARDIOTOXICITY; CHEMOTHERAPY; CHEMOTHERAPY INDUCED CARDIAC TOXICITY; ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE FAILURE; HUMAN; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; SCREENING; ANIMAL; BLOOD; CHEMICALLY INDUCED; HEART DISEASES;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS; CARDIOTOXICITY; HEART DISEASES; HUMANS; NATRIURETIC PEPTIDE, BRAIN; TROPONIN I; TROPONIN T;

EID: 84924455468     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2014.10.013     Document Type: Review

References (161)

1. Eschenhagen T., Force T., Ewer M.S., de Keulenaer G., Suter T.M., Anker S.D., et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2011, 13(1):1-10.
2. Shan K., Lincoff A.M., Young J.B. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996, 125(1):47-58.
3. Steinberg J.S., Cohen A.J., Wasserman A.G., Cohen P., Ross A.M. Acute arrhythmogenicity of doxorubicin administration. Cancer 1987, 60(6):1213-1218.
4. Aleman B.M., van den Belt-Dusebout A.W., De Bruin M.L., van 't Veer M.B., Baaijens M.H., de Boer J.P., et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007, 109(5):1878-1886.
5. McMurray J.J., Adamopoulos S., Anker S.D., Auricchio A., Bohm M., Dickstein K., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012, 14(8):803-869.
6. Ewer M.S., Lenihan D.J. Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground?. J Clin Oncol 2008, 26(8):1201-1203.
7. Ewer M.S., Lippman S.M. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 2005, 23(13):2900-2902.
8. Raj S., Franco V.I., Lipshultz S.E. Anthracycline-induced cardiotoxicity: a review of pathophysiology, diagnosis, and treatment. Curr Treat Options Cardiovasc Med 2014, 16(6):315.
9. Doroshow J.H. Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res 1983, 43(2):460-472.
10. Abd El-Aziz M.A., Othman A.I., Amer M., El-Missiry M.A. Potential protective role of angiotensin-converting enzyme inhibitors captopril and enalapril against adriamycin-induced acute cardiac and hepatic toxicity in rats. J Appl Toxicol 2001, 21(6):469-473.
11. Lotrionte M., Biondi-Zoccai G., Abbate A., Lanzetta G., D'Ascenzo F., Malavasi V., et al. Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity. Am J Cardiol 2013, 112(12):1980-1984.
12. Smith L.A., Cornelius V.R., Plummer C.J., Levitt G., Verrill M., Canney P., et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 2010, 10:337.
13. Friedman M.A., Bozdech M.J., Billingham M.E., Rider A.K. Doxorubicin cardiotoxicity. Serial endomyocardial biopsies and systolic time intervals. JAMA 1978, 240(15):1603-1606.
14. Steinherz L.J., Steinherz P.G., Tan C.T., Heller G., Murphy M.L. Cardiac toxicity 4 to 20years after completing anthracycline therapy. JAMA 1991, 266(12):1672-1677.
15. Volkova M., Russell R. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev 2011, 7(4):214-220.
16. Bristow M.R., Mason J.W., Billingham M.E., Daniels J.R. Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. Am Heart J 1981, 102(4):709-718.
17. Gottdiener J.S., Appelbaum F.R., Ferrans V.J., Deisseroth A., Ziegler J. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med 1981, 141(6):758-763.
18. Auner H.W., Tinchon C., Brezinschek R.I., Eibl M., Sormann S., Maizen C., et al. Monitoring of cardiac function by serum cardiac troponin T levels, ventricular repolarisation indices, and echocardiography after conditioning with fractionated total body irradiation and high-dose cyclophosphamide. Eur J Haematol 2002, 69(1):1-6.
19. Auner H.W., Tinchon C., Linkesch W., Tiran A., Quehenberger F., Link H., et al. Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann Hematol 2003, 82(4):218-222.
20. Fujimaki K., Maruta A., Yoshida M., Sakai R., Tanabe J., Koharazawa H., et al. Severe cardiac toxicity in hematological stem cell transplantation: predictive value of reduced left ventricular ejection fraction. Bone Marrow Transplant 2001, 27(3):307-310.
21. Zver S., Zadnik V., Cernelc P., Kozelj M. Cardiac toxicity of high-dose cyclophosphamide and melphalan in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation. Int J Hematol 2008, 88(2):227-236.
22. Kuittinen T., Jantunen E., Vanninen E., Mussalo H., Vuolteenaho O., Ala-Kopsala M., et al. Cardiac effects within 3months of BEAC high-dose therapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation. Eur J Haematol 2006, 77(2):120-127.
23. Jones R.L., Ewer M.S. Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs. Expert Rev Anticancer Ther 2006, 6(9):1249-1269.
24. Rowinsky E.K., McGuire W.P., Guarnieri T., Fisherman J.S., Christian M.C., Donehower R.C. Cardiac disturbances during the administration of taxol. J Clin Oncol 1991, 9(9):1704-1712.
25. Albini A., Pennesi G., Donatelli F., Cammarota R., De Flora S., Noonan D.M. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 2010, 102(1):14-25.
26. Schober C., Papageorgiou E., Harstrick A., Bokemeyer C., Mugge A., Stahl M., et al. Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer. Cancer 1993, 72(7):2242-2247.
27. Tsibiribi P., Descotes J., Lombard-Bohas C., Barel C., Bui-Xuan B., Belkhiria M., et al. Cardiotoxicity of 5-fluorouracil in 1350 patients with no prior history of heart disease. Bull Cancer 2006, 93(3):E27-E30.
28. Yeh E.T., Bickford C.L. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009, 53(24):2231-2247.
29. Sorrentino M.F., Kim J., Foderaro A.E., Truesdell A.G. 5-fluorouracil induced cardiotoxicity: review of the literature. Cardiol J 2012, 19(5):453-458.
30. Labianca R., Beretta G., Clerici M., Fraschini P., Luporini G. Cardiac toxicity of 5-fluorouracil: a study on 1083 patients. Tumori 1982, 68(6):505-510.
31. Bang Y.J., Van Cutsem E., Feyereislova A., Chung H.C., Shen L., Sawaki A., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376(9742):687-697.
32. Suter T.M., Cook-Bruns N., Barton C. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. Breast 2004, 13(3):173-183.
33. Ewer M.S., Vooletich M.T., Durand J.B., Woods M.L., Davis J.R., Valero V., et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005, 23(31):7820-7826.
34. Crone S.A., Zhao Y.Y., Fan L., Gu Y., Minamisawa S., Liu Y., et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002, 8(5):459-465.
35. Onitilo A.A., Engel J.M., Stankowski R.V., Liang H., Berg R.L., Doi S.A. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study. Breast Cancer Res Treat 2012, 134(1):291-298.
36. Russell S.D., Blackwell K.L., Lawrence J., Pippen J.E., Roe M.T., Wood F., et al. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol 2010, 28(21):3416-3421.
37. Smith I., Procter M., Gelber R.D., Guillaume S., Feyereislova A., Dowsett M., et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007, 369(9555):29-36.
38. Ewer S.M., Ewer M.S. Cardiotoxicity profile of trastuzumab. Drug Saf 2008, 31(6):459-467.
39. Balduzzi S., Mantarro S., Guarneri V., Tagliabue L., Pistotti V., Moja L., et al. Trastuzumab-containing regimens for metastatic breast cancer. Cochrane Database Syst Rev 2014, 6. [CD006242].
40. Ozcelik C., Erdmann B., Pilz B., Wettschureck N., Britsch S., Hubner N., et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci U S A 2002, 99(13):8880-8885.
41. Pivot X., Romieu G., Debled M., Pierga J.Y., Kerbrat P., Bachelot T., et al. 6months versus 12months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol 2013, 14(8):741-748.
42. Vaz-Luis I., Keating N.L., Lin N.U., Lii H., Winer E.P., Freedman R.A. Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study. J Clin Oncol 2014, 32(9):927-934.
43. Schmidinger M., Zielinski C.C., Vogl U.M., Bojic A., Bojic M., Schukro C., et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008, 26(32):5204-5212.
44. Chu T.F., Rupnick M.A., Kerkela R., Dallabrida S.M., Zurakowski D., Nguyen L., et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007, 370(9604):2011-2019.
45. Richards C.J., Je Y., Schutz F.A., Heng D.Y., Dallabrida S.M., Moslehi J.J., et al. Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. J Clin Oncol 2011, 29(25):3450-3456.
46. Force T., Krause D.S., Van Etten R.A. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007, 7(5):332-344.
47. Kerkela R., Grazette L., Yacobi R., Iliescu C., Patten R., Beahm C., et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006, 12(8):908-916.
48. Perik P.J., Rikhof B., de Jong F.A., Verweij J., Gietema J.A., van der Graaf W.T. Results of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicity. Ann Oncol 2008, 19(2):359-361.
49. Herman E.H., Knapton A., Rosen E., Thompson K., Rosenzweig B., Estis J., et al. A multifaceted evaluation of imatinib-induced cardiotoxicity in the rat. Toxicol Pathol 2011, 39(7):1091-1106.
50. Ribeiro A.L., Marcolino M.S., Bittencourt H.N., Barbosa M.M., Nunes Mdo C., Xavier V.F., et al. An evaluation of the cardiotoxicity of imatinib mesylate. Leuk Res 2008, 32(12):1809-1814.
51. Gambacorti-Passerini C., Tornaghi L., Franceschino A., Piazza R., Corneo G., Pogliani E. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Nat Med 2007, 13(1):13-14. [author reply 5-6].
52. Park Y.H., Park H.J., Kim B.S., Ha E., Jung K.H., Yoon S.H., et al. BNP as a marker of the heart failure in the treatment of imatinib mesylate. Cancer Lett 2006, 243(1):16-22.
53. Kelly K., Swords R., Mahalingam D., Padmanabhan S., Giles F.J. Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors. Target Oncol 2009, 4(2):99-105.
54. Gressett S.M., Shah S.R. Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother 2009, 43(3):490-501.
55. Hawkes E.A., Okines A.F., Plummer C., Cunningham D. Cardiotoxicity in patients treated with bevacizumab is potentially reversible. J Clin Oncol 2011, 29(18):e560-e562.
56. Khawaja M.Z., Cafferkey C., Rajani R., Redwood S., Cunningham D. Cardiac complications and manifestations of chemotherapy for cancer. Heart 2014, 100(14):1133-1140.
57. Morrow D.A., Cannon C.P., Jesse R.L., Newby L.K., Ravkilde J., Storrow A.B., et al. National Academy Of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation 2007, 115(13):e356-e375.
58. Yancy C.W., Jessup M., Bozlurt B., Butler J., Casey D.E., Drazner M.H., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013, 62(16):e147-e239.
59. Hayes D.F. OMICS-based personalized oncology: if it is worth doing, it is worth doing well!. BMC Med 2013, 11:221.
60. Morrow D.A., de Lemos J.A. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 2007, 115(8):949-952.
61. Apple F.S., Collinson P.O. Biomarkers ITFoCAoC. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem 2012, 58(1):54-61.
62. Henry N.L., Hayes D.F. Cancer biomarkers. Mol Oncol 2012, 6(2):140-146.
63. Febbo P.G., Ladanyi M., Aldape K.D., De Marzo A.M., Hammond M.E., Hayes D.F., et al. NCCN Task Force report: evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw 2011, 9(Suppl. 5):S1-S32. [quiz S3].
64. Wallace K.B., Hausner E., Herman E., Holt G.D., MacGregor J.T., Metz A.L., et al. Serum troponins as biomarkers of drug-induced cardiac toxicity. Toxicol Pathol 2004, 32(1):106-121.
65. Missov E., Calzolari C., Davy J.M., Leclercq F., Rossi M., Pau B. Cardiac troponin I in patients with hematologic malignancies. Coron Artery Dis 1997, 8(8-9):537-541.
66. Herman E.H., Lipshultz S.E., Rifai N., et al. Use of cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity. Cancer Res 1998, 58(2):195-197.
67. Herman E.H., Lipshultz S.E., Rifai N., Zhang J., Papoian T., Yu Z.X., et al. Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 1999, 17(7):2237-2243.
68. Cardinale D., Sandri M.T., Colombo A., Colombo N., Boeri M., Lamantia G., et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004, 109(22):2749-2754.
69. Sawaya H., Sebag I.A., Plana J.C., Januzzi J.L., Ky B., Tan T.C., et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 2012, 5(5):596-603.
70. Lee H.S., Son C.B., Shin S.H., Kim Y.S. Clinical correlation between brain natriuretic peptide and anthracycline-induced cardiac toxicity. Cancer Res Treat Off J Korean Cancer Assoc 2008, 40(3):121-126.
71. Mavinkurve-Groothuis A.M., Marcus K.A., Pourier M., Loonen J., Feuth T., Hoogerbrugge P.M., et al. Myocardial 2D strain echocardiography and cardiac biomarkers in children during and shortly after anthracycline therapy for acute lymphoblastic leukaemia (ALL): a prospective study. Eur Heart J Cardiovasc Imaging 2013, 14(6):562-569.
72. Lipshultz S.E., Rifai N., Sallan S.E., Lipsitz S.R., Dalton V., Sacks D.B., et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 1997, 96(8):2641-2648.
73. Specchia G., Buquicchio C., Pansini N., Serio F., Liso V., Pastore D., et al. Monitoring of cardiac function n the basis of serum troponin I levels in patients with acute leukemia treated with anthracyclines. J Lab Clin Med 2005, 145(4):212-220.
74. Kilickap S., Barista I., Akgul E., Aytemir K., Aksoyek S., Aksoy S., et al. cTnT can be a useful marker for early detection of anthracycline cardiotoxicity. Ann Oncol 2005, 16(5):798-804.
75. Ruggiero A., De Rosa G., Rizzo D., Leo A., Maurizi P., De Nisco A., et al. Myocardial performance index and biochemical markers for early detection of doxorubicin-induced cardiotoxicity in children with acute lymphoblastic leukaemia. Int J Clin Oncol 2013, 18(5):927-933.
76. Dolci A., Dominici R., Cardinale D., Sandri M.T., Panteghini M. Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: systematic review of the literature and recommendations for use. Am J Clin Pathol 2008, 130(5):688-695.
77. Ky B., Putt M., Sawaya H., French B., Januzzi J.L., Sebag I.A., et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol 2014, 63(8):809-816.
78. Cardinale D., Sandri M.T., Martinoni A., Borghini E., Civelli M., Lamantia G., et al. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol 2002, 13(5):710-715.
79. Garrone O., Crosetto N., Lo Nigro C., Catzeddu T., Vivenza D., Monteverde M., et al. Prediction of anthracycline cardiotoxicity after chemotherapy by biomarkers kinetic analysis. Cardiovasc Toxicol 2012, 12(2):135-142.
80. Mornos C., Petrescu L. Early detection of anthracycline-mediated cardiotoxicity: the value of considering both global longitudinal left ventricular strain and twist. Can J Physiol Pharmacol 2013, 91(8):601-607.
81. Sawaya H., Sebag I.A., Plana J.C., Januzzi J.L., Ky B., Cohen V., et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol 2011, 107(9):1375-1380.
82. Cardinale D., Colombo A., Sandri M.T., Lamantia G., Colombo N., Civelli M., et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006, 114(23):2474-2481.
83. Cardinale D., Sandri M.T., Martinoni A., Tricca A., Civelli M., Lamantia G., et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 2000, 36(2):517-522.
84. Sandri M.T., Cardinale D., Zorzino L., Passerini R., Lentati P., Martinoni A., et al. Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy. Clin Chem 2003, 49(2):248-252.
85. Drafts B.C., Twomley K.M., D'Agostino R., Lawrence J., Avis N., Ellis L.R., et al. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging 2013, 6(8):877-885.
86. Romano S., Fratini S., Ricevuto E., Procaccini V., Stifano G., Mancini M., et al. Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients. Br J Cancer 2011, 105(11):1663-1668.
87. Feola M., Garrone O., Occelli M., Francini A., Biggi A., Visconti G., et al. Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide. Int J Cardiol 2011, 148(2):194-198.
88. Erkus B., Demirtas S., Yarpuzlu A.A., Can M., Genc Y., Karaca L. Early prediction of anthracycline induced cardiotoxicity. Acta Paediatr 2007, 96(4):506-509.
89. Fink F.M., Genser N., Fink C., Falk M., Mair J., Maurer-Dengg K., et al. Cardiac troponin T and creatine kinase MB mass concentrations in children receiving anthracycline chemotherapy. Med Pediatr Oncol 1995, 25(3):185-189.
90. Kismet E., Varan A., Ayabakan C., Alehan D., Portakal O., Buyukpamukcu M. Serum troponin T levels and echocardiographic evaluation in children treated with doxorubicin. Pediatr Blood Cancer 2004, 42(3):220-224.
91. Dodos F., Halbsguth T., Erdmann E., Hoppe U.C. Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults. Clin Res Cardiol 2008, 97(5):318-326.
92. Grover S., Leong D.P., Chakrabarty A., Joerg L., Kotasek D., Cheong K., et al. Left and right ventricular effects of anthracycline and trastuzumab chemotherapy: a prospective study using novel cardiac imaging and biochemical markers. Int J Cardiol 2013, 168(6):5465-5467.
93. Koseoglu V., Berberoglu S., Karademir S., Kismet E., Yurttutan N., Demirkaya E., et al. Cardiac troponin I: is it a marker to detect cardiotoxicity in children treated with doxorubicin?. Turk J Pediatr 2005, 47(1):17-22.
94. Kremer L.C., Bastiaansen B.A., Offringa M., Lam J., van Straalen J.P., de Winter R.J., et al. Troponin T in the first 24hours after the administration of chemotherapy and the detection of myocardial damage in children. Eur J Cancer 2002, 38(5):686-689.
95. Soker M., Kervancioglu M. Plasma concentrations of NT-pro-BNP and cardiac troponin-I in relation to doxorubicin-induced cardiomyopathy and cardiac function in childhood malignancy. Saudi Med J 2005, 26(8):1197-1202.
96. Berridge B.R., Pettit S., Walker D.B., Jaffe A.S., Schultze A.E., Herman E., et al. A translational approach to detecting drug-induced cardiac injury with cardiac troponins: consensus and recommendations from the Cardiac Troponins Biomarker Working Group of the Health and Environmental Sciences Institute. Am Heart J 2009, 158(1):21-29.
97. Dhesy-Thind S., Kumar V., Snider-McNair A., Shortt C., Mukherjee S.D., Ellis P., et al. Cardiac and inflammation biomarker profile after initiation of adjuvant trastuzumab therapy. Clin Chem 2013, 59(1):327-329.
98. Horacek J.M., Tichy M., Pudil R., Jebavy L. Glycogen phosphorylase BB could be a new circulating biomarker for detection of anthracycline cardiotoxicity. Ann Oncol 2008, 19(9):1656-1657.
99. Horacek J.M., Pudil R., Tichy M., Jebavy L., Strasova A., Ulrychova M., et al. Cardiac troponin I seems to be superior to cardiac troponin T in the early detection of cardiac injury associated with anthracycline treatment. Onkologie 2008, 31(10):559-560.
100. Cardinale D., Colombo A., Torrisi R., Sandri M.T., Civelli M., Salvatici M., et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 2010, 28(25):3910-3916.
101. Shortt C., Mansour M., Dhesy-Thind S., Hotte S., Leong D., Worster A., et al. Myocardial injury in cancer patients - are there differences between women and men?. AACC Ann Meet 2014, S222. [B-353].
102. D'Alessandro R., Masarone D., Buono A., Gravino R., Rea A., Salerno G., et al. Natriuretic peptides: molecular biology, pathophysiology and clinical implications for the cardiologist. Future Cardiol 2013, 9(4):519-534.
103. Gimeno E., Gomez M., Gonzalez J.R., Comin J., Alvarez-Larran A., Sanchez-Gonzalez B., et al. NT-proBNP: a cardiac biomarker to assess prognosis in non-Hodgkin lymphoma. Leuk Res 2011, 35(6):715-720.
104. Geiger S., Stemmler H.J., Suhl P., Stieber P., Lange V., Baur D., et al. Anthracycline-induced cardiotoxicity: cardiac monitoring by continuous wave-Doppler ultrasound cardiac output monitoring and correlation to echocardiography. Onkologie 2012, 35(5):241-246.
105. Aggarwal S., Pettersen M.D., Bhambhani K., Gurczynski J., Thomas R., L'Ecuyer T. B-type natriuretic peptide as a marker for cardiac dysfunction in anthracycline-treated children. Pediatr Blood Cancer 2007, 49(6):812-816.
106. Okumura H., Iuchi K., Yoshida T., Nakamura S., Takeshima M., Takamatsu H., et al. Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity. Acta Haematol 2000, 104(4):158-163.
107. Lipshultz S.E., Miller T.L., Scully R.E., Lipsitz S.R., Rifai N., Silverman L.B., et al. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol 2012, 30(10):1042-1049.
108. Suzuki T., Hayashi D., Yamazaki T., Mizuno T., Kanda Y., Komuro I., et al. Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J 1998, 136(2):362-363.
109. Sandri M.T., Salvatici M., Cardinale D., Zorzino L., Passerini R., Lentati P., et al. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction?. Clin Chem 2005, 51(8):1405-1410.
110. Bauch M., Ester A., Kimura B., Victorica B.E., Kedar A., Phillips M.I. Atrial natriuretic peptide as a marker for doxorubicin-induced cardiotoxic effects. Cancer 1992, 69(6):1492-1497.
111. Daugaard G., Lassen U., Bie P., Pedersen E.B., Jensen K.T., Abildgaard U., et al. Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction. Eur J Heart Fail 2005, 7(1):87-93.
112. Meinardi M.T., van Veldhuisen D.J., Gietema J.A., Dolsma W.V., Boomsma F., van den Berg M.P., et al. Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol 2001, 19(10):2746-2753.
113. Poutanen T., Tikanoja T., Riikonen P., Silvast A., Perkkio M. Long-term prospective follow-up study of cardiac function after cardiotoxic therapy for malignancy in children. J Clin Oncol 2003, 21(12):2349-2356.
114. Hayakawa H., Komada Y., Hirayama M., Hori H., Ito M., Sakurai M. Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. Med Pediatr Oncol 2001, 37(1):4-9.
115. Pichon M.F., Cvitkovic F., Hacene K., Delaunay J., Lokiec F., Collignon M.A., et al. Drug-induced cardiotoxicity studied by longitudinal B-type natriuretic peptide assays and radionuclide ventriculography. In Vivo 2005, 19(3):567-576.
116. Nousiainen T., Jantunen E., Vanninen E., Remes J., Vuolteenaho O., Hartikainen J. Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma. Eur J Haematol 1999, 62(2):135-141.
117. Kouloubinis A., Kaklamanis L., Ziras N., Sofroniadou S., Makaritsis K., Adamopoulos S., et al. ProANP and NT-proBNP levels to prospectively assess cardiac function in breast cancer patients treated with cardiotoxic chemotherapy. Int J Cardiol 2007, 122(3):195-201.
118. Sherief L.M., Kamal A.G., Khalek E.A., Kamal N.M., Soliman A.A., Esh A.M. Biomarkers and early detection of late onset anthracycline-induced cardiotoxicity in children. Hematology 2012, 17(3):151-156.
119. Lipshultz S.E., Landy D.C., Lopez-Mitnik G., Lipsitz S.R., Hinkle A.S., Constine L.S., et al. Cardiovascular status of childhood cancer survivors exposed and unexposed to cardiotoxic therapy. J Clin Oncol 2012, 30(10):1050-1057.
120. Ekstein S., Nir A., Rein A.J., Perles Z., Bar-Oz B., Salpeter L., et al. N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children. J Pediatr Hematol Oncol 2007, 29(7):440-444.
121. Nousiainen T., Jantunen E., Vanninen E., Remes J., Puustinen J., Rantala A., et al. Acute neurohumoral and cardiovascular effects of idarubicin in leukemia patients. Eur J Haematol 1998, 61(5):347-353.
122. Broeyer F.J., Osanto S., Ritsema van Eck H.J., van Steijn A.Q., Ballieux B.E., Schoemaker R.C., et al. Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy. J Cancer Res Clin Oncol 2008, 134(9):961-968.
123. Mladosievicova B., Urbanova D., Radvanska E., Slavkovsky P., Simkova I. Role of NT-proBNP in detection of myocardial damage in childhood leukemia survivors treated with and without anthracyclines. J Exp Clin Cancer Res 2012, 31:86.
124. Morris P.G., Chen C., Steingart R., Fleisher M., Lin N., Moy B., et al. Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib. Clin Cancer Res 2011, 17(10):3490-3499.
125. Horacek J.M., Tichy M., Jebavy L., Ulrychova M., Pudil R. Glycogen phosphorylase BB as a marker of cardiac toxicity during high-dose chemotherapy followed by hematopoietic cell transplantation. Ann Oncol 2007, 18(12):2041.
126. Horacek J.M., Tichy M., Jebavy L., Pudil R., Ulrychova M., Maly J. Use of multiple biomarkers for evaluation of anthracycline-induced cardiotoxicity in patients with acute myeloid leukemia. Exp Oncol 2008, 30(2):157-159.
127. Fichtlscherer S., Zeiher A.M., Dimmeler S. Circulating microRNAs: biomarkers or mediators of cardiovascular diseases?. Arterioscler Thromb Vasc Biol 2011, 31(11):2383-2390.
128. Mendell J.T., Olson E.N. MicroRNAs in stress signaling and human disease. Cell 2012, 148(6):1172-1187.
129. Horie T., Ono K., Nishi H., Nagao K., Kinoshita M., Watanabe S., et al. Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway. Cardiovasc Res 2010, 87(4):656-664.
130. Wang J.F., Yu M.L., Yu G., Bian J.J., Deng X.M., Wan X.J., et al. Serum miR-146a and miR-223 as potential new biomarkers for sepsis. Biochem Biophys Res Commun 2010, 394(1):184-188.
131. Pauley K.M., Stewart C.M., Gauna A.E., Dupre L.C., Kuklani R., Chan A.L., et al. Altered miR-146a expression in Sjogren's syndrome and its functional role in innate immunity. Eur J Immunol 2011, 41(7):2029-2039.
132. Brase J.C., Wuttig D., Kuner R., Sultmann H. Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer 2010, 9:306.
133. Haghikia A., Podewski E., Libhaber E., Labidi S., Fischer D., Roentgen P., et al. Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. Basic Res Cardiol 2013, 108(4):366.
134. Fan K.L., Zhang H.F., Shen J., Zhang Q., Li X.L. Circulating microRNAs levels in Chinese heart failure patients caused by dilated cardiomyopathy. Indian Heart J 2013, 65(1):12-16.
135. Lipshultz S.E., Rifai N., Dalton V.M., Levy D.E., Silverman L.B., Lipsitz S.R., et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 2004, 351(2):145-153.
136. Lipshultz S.E., Scully R.E., Lipsitz S.R., Sallan S.E., Silverman L.B., Miller T.L., et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol 2010, 11(10):950-961.
137. Herman E.H., Zhang J., Rifai N., Lipshultz S.E., Hasinoff B.B., Chadwick D.P., et al. The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity. Cancer Chemother Pharmacol 2001, 48(4):297-304.
138. Swain S.M., Whaley F.S., Gerber M.C., Weisberg S., York M., Spicer D., et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 1997, 15(4):1318-1332.
139. Speyer J.L., Green M.D., Sanger J., Zeleniuch-Jacquotte A., Kramer E., Rey M., et al. A prospective randomized trial of ICRF-187 for prevention of cumulative doxorubicin-induced cardiac toxicity in women with breast cancer. Cancer Treat Rev 1990, 17(2-3):161-163.
140. Tebbi C.K., London W.B., Friedman D., Villaluna D., De Alarcon P.A., Constine L.S., et al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol 2007, 25(5):493-500.
141. Barry E.V., Vrooman L.M., Dahlberg S.E., Neuberg D.S., Asselin B.L., Athale U.H., et al. Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. J Clin Oncol 2008, 26(7):1106-1111.
142. van Dalen E.C., Caron H.N., Dickinson H.O., Kremer L.C. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2011, 6. [CD003917].
143. Okumura K., Jin D., Takai S., Miyazaki M. Beneficial effects of angiotensin-converting enzyme inhibition in adriamycin-induced cardiomyopathy in hamsters. Jpn J Pharmacol 2002, 88(2):183-188.
144. Cadeddu C., Piras A., Mantovani G., Deidda M., Dessi M., Madeddu C., et al. Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. Am Heart J 2010, 160(3):487 e1-7.
145. Tokudome T., Mizushige K., Noma T., Manabe K., Murakami K., Tsuji T., et al. Prevention of doxorubicin (adriamycin)-induced cardiomyopathy by simultaneous administration of angiotensin-converting enzyme inhibitor assessed by acoustic densitometry. J Cardiovasc Pharmacol 2000, 36(3):361-368.
146. Sacco G., Bigioni M., Evangelista S., Goso C., Manzini S., Maggi C.A. Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat. Eur J Pharmacol 2001, 414(1):71-78.
147. al-Shabanah O., Mansour M., el-Kashef H., al-Bekairi A. Captopril ameliorates myocardial and hematological toxicities induced by adriamycin. Biochem Mol Biol Int 1998, 45(2):419-427.
148. Vaynblat M., Shah H.R., Bhaskaran D., Ramdev G., Davis W.J., Cunningham J.N., et al. Simultaneous angiotensin converting enzyme inhibition moderates ventricular dysfunction caused by doxorubicin. Eur J Heart Fail 2002, 4(5):583-586.
149. Jensen B.V., Nielsen S.L., Skovsgaard T. Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy. Lancet 1996, 347(8997):297-299.
150. Nakamae H., Tsumura K., Terada Y., Nakane T., Nakamae M., Ohta K., et al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer 2005, 104(11):2492-2498.
151. Colombo A., Sandri M.T., Salvatici M., Cipolla C.M., Cardinale D. Cardiac complications of chemotherapy: role of biomarkers. Curr Treat Options Cardiovasc Med 2014, 16(6):313.
152. Fazio S., Palmieri E.A., Ferravante B., Bone F., Biondi B., Sacca L. Doxorubicin-induced cardiomyopathy treated with carvedilol. Clin Cardiol 1998, 21(10):777-779.
153. Yue T.L., McKenna P.J., Ruffolo R.R., Feuerstein G. Carvedilol, a new beta-adrenoceptor antagonist and vasodilator antihypertensive drug, inhibits superoxide release from human neutrophils. Eur J Pharmacol 1992, 214(2-3):277-280.
154. Matsui H., Morishima I., Numaguchi Y., Toki Y., Okumura K., Hayakawa T. Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats. Life Sci 1999, 65(12):1265-1274.
155. Munzel T., Gori T. Nebivolol: the somewhat-different beta-adrenergic receptor blocker. J Am Coll Cardiol 2009, 54(16):1491-1499.
156. Mukai Y., Yoshida T., Nakaike R., Mukai N., Iwato K., Kyo T., et al. Five cases of anthracycline-induced cardiomyopathy effectively treated with carvedilol. Intern Med 2004, 43(11):1087-1088.
157. Kalay N., Basar E., Ozdogru I., Er O., Cetinkaya Y., Dogan A., et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006, 48(11):2258-2262.
158. Kaya M.G., Ozkan M., Gunebakmaz O., Akkaya H., Kaya E.G., Akpek M., et al. Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study. Int J Cardiol 2013, 167(5):2306-2310.
159. Batist G., Ramakrishnan G., Rao C.S., Chandrasekharan A., Gutheil J., Guthrie T., et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001, 19(5):1444-1454.
160. O'Brien M.E., Wigler N., Inbar M., Rosso R., Grischke E., Santoro A., et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004, 15(3):440-449.
161. Lenihan D.J. Cardiac biomarkers, cardiotoxicity, and active collaboration: is this the final frontier or the wave we should catch?. J Am Coll Cardiol 2014, 63(8):817-818.